Systematic assessment of decision models in Parkinson's disease

Value in Health

Volumn 7, Issue 5, 2004, Pages 610-626

  Siebert, Uwe ^a,b,c   Bornschein, Bernhard ^c,d   Walbert, Tobias ^b,d   Dodel, Richard C ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD CENTER FOR RISK ANALYSIS   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Cost effectiveness analysis; Decision analysis; Parkinson's disease; Systematic review

Indexed keywords

BROMOCRIPTINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 6344280753     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.75012.x     Document Type: Article

References (73)

1. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18:19-31.
2. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-82.
3. Sutcliffe RL, Meara JR. Parkinson's disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand 1995;92:443-50.
4. Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson's disease in a Scottish city. Brit Med J 1986;292:534-6.
5. Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10:331-9.
6. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl 1):S2-11.
7. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58.
8. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-12.
9. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl 5):S1-88.
10. Oertel WH, Quinn NP. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, Kennard C, Dichgans J, eds., Neurological Disorders: Course and Treatment. San Diego: Academic Press, 2003.
11. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98.
12. Honey C, Gross RE, Lozano AM. New developments in the surgery for Parkinson's disease. Can J Neurol Sci 1999;26(Suppl 2):S45-52.
13. Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001;56:548-51.
14. Raiffa H. Decision Analysis: Introductory Lectures on Choices Under Uncertainty. New York: Random House, 1968.
15. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21.
16. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia: WB. Saunders Company, 1980.
17. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). New York: Oxford University Press, 1997.
18. Hunink MG, Glasziou PP, Siegel JE, et al. Decision Making in Health and Medicine. Integrating Evidence and Values. Cambridge: Cambridge University Press, 2001.
19. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6:9-17.
20. Kurlan R, Clark S, Shoulson I, et al. Economic impact of protective therapy for early Parkinson's disease. Ann Neurol 1988;24:153.
21. Siderowf A, Holloway R, Mushlin A. Cost-effectiveness of pallidotomy and add-on medical therapy in advanced Parkinson's disease. Ann Neurol 1998;44:517.
22. Smala AM, Berger K, Spottke EA, et al. Cost-effectiveness of cabergoline. Parkinsonism Relat Disord 2001;7(Suppl):S105.
23. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
24. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
25. Faglioni P, Botti C, Scarpa M, et al. Learning and forgetting processes in Parkinson's disease: a model-based approach to disentangling storage, retention and retrieval contributions. Neuropsychologia 1997;35:767-79.
26. Faglioni P, Saetti MC, Botti C. Verbal learning strategies in Parkinson's disease. Neuropsychology 2000;14:456-70.
27. Hsieh S, Hwang WJ, Tsai JJ, Tsai CY. Visuospatial orienting of attention in Parkinson's disease. Percept Mot Skills 1996;82:1307-15.
28. Hsieh S, Hwang WJ, Tsai JJ, Tsai CY. Precued shifting of attention between cognitive sets in Parkinson patients. Psychol Rep 1996;78:815-23.
29. Sharpe MH. Patients with early Parkinson's disease are not impaired on spatial orientating of attention. Cortex 1990;26:515-24.
30. El-Deredy W, Branston NM, Samuel M, et al. Firing patterns of pallidal cells in Parkinsonian patients correlate with their pre-pallidotomy clinical scores. Neuroreport 2000;11:3413-18.
31. Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson's disease nurse specialist. Int J Nurs Stud 2000;37:337-49.
32. Anonymous. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol 2000;23:34-44.
33. Hempel AG, Wagner ML, Maaty MA, Sage JI. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother 1998;32:878-83.
34. LeWitt P, Oakes D, Cui L. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. Mov Disord 1997;12:183-9.
35. Montgomery EB Jr, Lieberman A, Singh G, Fries JF. Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. PROPATH Advisory Board [Comment]. Am J Med 1994;97:429-35.
36. Martinez-Martin P. An introduction to the concept of 'quality of life in Parkinson's disease'. J Neurol 1998;245(Suppl 1):S2-6.
37. Nuijten MJC. Bridging decision analytic modelling with a cross-sectional study - application to Parkinson's disease. Pharmacoeconomics 2000;17:227-36.
38. MacMahon DG. Parkinson's disease nurse specialists - an important role in disease management. Neurology 1999;52(Suppl 3):S21-5.
39. Spottke EA, Volkmann J, Lorenz D, et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249:759-66.
40. Dewey RB, Rao SD, Holmburg SL, Victor RG. Ergotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failure. Eur J Neurol 1998;5:593-9.
41. Dodel RC, Eggert K, Oertel WH. Economical research on Parkinson's disease: a review of the literature. Eur J Neurol 1999;6(Suppl 2):S3-15.
42. Dodel RC, Spottke EA, Oertel WH. Quality of life and costs of neurosurgical procedures in the treatment of Parkinson's disease. Aktuel Neurol 2000;27(Suppl 1):S61-9.
43. Jost WH. Costs in the treatment of parkinsonism. J Neurol 2000;247(Suppl 4):S31-3.
44. Pogarell O, Oertel WH. New dopamine agonists for the treatment of parkinsons-disease. Aktuel Neurol 1998;25:202-9.
45. Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000;15:439-45.
46. Linna M, Taimela E, Apajasalo M, Martilla RJ. Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease. Expert Rev Pharmacoeconomics Outcomes Res 2002;2:91-7.
47. Palmer CS, Nuijten MJC, Schmier JK, et al. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 2002;20:617-28.
48. Iskedjian M, Einarson TR. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Pharmacoeconomics 2003;21:115-27.
49. Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998;14:541-57.
50. Davey P, Rajan N, Lees M, Aristides M. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model. Value Health 2001;4:308-15.
51. Nuijten MJC, van Iperen P, Palmer CS, et al. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 2001;4:316-28.
52. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinsons's disease. A cost-effectiveness analysis. Neurology 2001;57:663-71.
53. Shimbo T, Hira K, Takemura M, Fukui T. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. Pharmacoeconomics 2001;19:875-86.
54. Hawthorne G, Richardson J. Measuring the value of program outcomes: a review of multiattribute utility measures. Expert Rev Pharmacoeconomics Outcomes Res 2001;1:215-28.
55. Mitchell SL, Harper DW, Lau A, Bhalla R. Patterns of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology 2000;19:100-8.
56. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds., Recent Developments in Parkinson's Disease II. New York: Macmillan, 1987.
57. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112-18.
58. Dodel RC, Singer M, Köhne-Volland R, et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312.
59. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16:59-69.
60. Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson's disease: progression and mortality in the L-DOPA era. Adv Neurol 1996;69:3-11.
61. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
62. Riederer P, Sian J, Gerlach M. Is there neuroprotection in Parkinson syndrome? J Neurol 2000; 247(Suppl 4):S8-11.
63. Wermuth L, Stenager EN, Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995;92:55-8.
64. Treves TA, Pedro-Cuesta JD. Parkinsonism mortality in the US, 1. Time and space distribution. Acta Neurol Scand 1991;84:389-97.
65. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol 2002;249:138-45.
66. Poewe W, Gerstenbrand F. Klinische Klassifikation des Parkinson-Syndroms-Subtypen und Übergänge zu Multi-System-Atrophien. In: Schnabert G, Auff E, eds., Das Parkinson-Syndrom. Frankfurt: Editiones Roche, 1986.
67. Kuntz KM, Goldie SJ. Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias. Med Decis Making 2002;22:218-27.
68. Siebert U, Goldie SJ, Kuntz KM. Pharmacogenomics-Bias. Simulationen zur Fehlbeurteilung von Arzneimitteleffekten bei Nichtberücksichtigung genetischer Heterogenität (Abstract). 47th Annual Meeting of the German Society for Medical Informatics, Biometry, and Epidemiology (GMDS). Berlin, Germany, 2002.
69. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-77.
70. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001;4:348-61.
71. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27.
72. Anonymous. Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment. Pharmacoeconomics 2000;17:4434.
73. Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econ 2003;4:143-50.